X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SAR444836 is a phenylalanine hydroxylase (PAH) replacement gene therapy product based on adeno-associated virus (AAV) vector technology, which is investigated for the treatment of Phenylketonuria.
Lead Product(s): SAR444836
Therapeutic Area: Genetic Disease Product Name: SAR444836
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Details:
The AAV technology was developed by Avigen, which MediciNova acquired in 2009. The milestone payment is the result of the successful achievement of a clinical development milestone for a gene therapy product based on AAV vector technology that is covered under the agreement.
Lead Product(s): AAV Gene Therapy
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $11.0 million Upfront Cash: Undisclosed
Deal Type: Agreement October 04, 2023
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and Migration inhibitory factor. It is in late-stage clinical development for the treatment of chlorine gas-induced lung damage such as ARDS and acute lung injury.
Lead Product(s): Ibudilast
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: MN 166
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
MN-001 (tipelukast) is a novel, leukotriene receptor antagonist which inhibits phosphodiesterase and 5-lipoxygenase and is believed to reduce inflammation and prevent fibrosis. It received a notice of allowance for a new patent for treating advanced NASH in Canada.
Lead Product(s): Tipelukast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MN-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2023
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF).
Lead Product(s): Ibudilast
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: MN-166
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 09, 2023
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases.
Lead Product(s): Ibudilast
Therapeutic Area: Infections and Infectious Diseases Product Name: MN-166
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2023
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases.
Lead Product(s): Ibudilast
Therapeutic Area: Psychiatry/Psychology Product Name: MN 166
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 30, 2023
Details:
MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, including macrophage migration inhibitory factor (MIF). It is in late-stage clinical development for the treatment of neurodegenerative diseases.
Lead Product(s): Ibudilast,Temozolomide
Therapeutic Area: Oncology Product Name: MN-166
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
Details:
MN-001 (tipelukast) is a novel, orally administered, small molecule compound which reduces triglycerides (TG) in the blood. It has being investigated for the treatment or maintainence of type 2 diabetes and hypertriglyceridemia.
Lead Product(s): Tipelukast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MN-001
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
MN-001 (tipelukast), is a novel, orally administered, small molecule leukotriene receptor antagonist which inhibits phosphodiesterase (mainly 3 and 4) and 5-lipoxygenase (5-LO) and is believed to reduce inflammation and prevent fibrosis.
Lead Product(s): Tipelukast
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: MN-001
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
